Evidence map›Paper›PMID 42871965›Full record

ArticleiScience2026

Caihong Hu, Lijun Bian, Lin Luo, Zhonghua Zheng, Yuheng Chen, Xinxiang Gao, Fengyuan Li, Dinghua Yang, Yao Liu, Gang Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Caihong HuDepartment of Epidemiology, School of Public Health, Southeast University, Nanjing, China.
Lijun BianKey Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Lin LuoKey Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Zhonghua ZhengKey Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Yuheng ChenKey Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Xinxiang GaoKey Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Fengyuan LiDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Dinghua YangDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yao LiuDepartment of Pathology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Gang LiDepartment of General Surgery, Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Hao XuDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Caiwang YanKey Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Guangfu JinDepartment of Epidemiology, School of Public Health, Southeast University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal-type gastric cancer (IGC) progresses through the Correa cascade, yet the molecular determinants of this transition remain insufficiently defined. Using single-cell RNA sequencing (scRNA-seq) on matched normal, intestinal metaplasia, and tumor tissues from five patients, we identified eight epithelial subtypes, including a transitional enterocyte population that expanded along the disease trajectory. Pseudotime and network analyses revealed a progressive upregulation of

Indexed as

Correa cascadeG2/M checkpointintestinal metaplasiaintestinal-type gastric cancerPTTG1

Identifiers

PMID42871965
PMCPMC13659674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.